Eden Research Share Discussion Threads

[supersonico] 28/3/2020 17:45

Is the Parallel delayed Bayer 'formulation' issue sorted?

P22/80
BAYER ANIMAL HEALTH As previously announced, the launch of animal health products in the USA by Eden’s partner, Bayer Animal Health (‘Bayer’), has been delayed. This is due to the need for additional formulation work on one of the three initial products Bayer has developed. It is now anticipated that the launch of these products will take place in 2019, subject to successful completion of the additional formulation work. Bayer and Eden are working closely together to expedite matters, and both partners consider the launch of these products to be of high priority



As previously communicated, our work with Bayer Animal Health (covering companion animal products targeting dermatological diseases) encountered some challenges relating to one important formulation. The consequence of this is that the anticipated launch of a portfolio of Bayer products based upon Eden's encapsulation technology has been delayed. We remain actively engaged with Bayer to pursue solutions that would result in a viable product that would meet Bayer's stringent product profile requirements and we will provide an update to the market when appropriate.



OUR PRODUCTS - ANIMAL HEALTH 2020.

Eden’s partner for animal health applications in North America, Bayer Animal Health, continues to make steady progress with the four products that it is commercialising: a shampoo, a conditioner, a spray and an oticetic flush.

[supersonico] 26/3/2020 07:20

SIGNIFICANT SHAREHOLDERS
As of 24 March 2020, significant shareholdings in the share capital of Eden Research plc were:

BGF Investment Management Limited
58,333,000
15.34%

Sipcam Oxon S.p.A.
37,614,830
9.89%

Gresham House Asset Management Limited
27,845,445
7.32%

Cannacord Genuity Group Inc
22,684,000
5.96%

Amati AIM VCT plc
16,937,750
4.45%

Rathbone Nominees Limited
16,670,800
4.38%

HSBC Global Custody Nominee (UK) Limited
14,015,588
3.69%

JM Finn Nominees Limited
13,939,430
3.66%

[brucie5] 24/3/2020 11:39

My bad. Thanks.

[brucie5] 24/3/2020 10:59

Eden's current market capitalisation is £26 million

£14.54m on Stocko.

Where do you source your figure?

[investingisatrickygame] 24/3/2020 10:16

As a fellow shareholder rightly points out, it costs

$300 million to develop a commercially available pesticide to market. Currently that is £256 million.

$25-$50 million to bring a biopesticide to market. Currently that's £21-£42 million

Source:

Eden's current market capitalisation is £26 million and it has in its commercially available product portfolio, two biopesticides, Mevalone and Cedroz. By my reckoning, a reasonable argument suggests Eden's market cap should be at least £42-£84 million OR 11p-22p per share on these two products alone and that is without applying a multiple of 5,10 or a higher number. So if the sector sells on a multiple of 5, that would imply a minimum 55p share price.

That tells me there is enormous headway in today's share price purely based on the commonly accepted costs of developing a product to market.

It should be understood that this doesn't allow for Corteva, or a possible insecticide or anything else in the pipeline with Sustaine.


The Coronavirus is interesting in that everyone is searching for a vaccine asap because clearly the virus is deadly. So alot of R & D going on to find a solution. Bill Gates has been banging on about vaccines for years and clearly, rightly so.

It wouldn't surprise me if this heightens grants for R & D in the food chain/agriculture sector from which companies like Eden may benefit.

Also, Roundup, as is legally binding by the courts in the USA has determined that pesticides are a killer in the respect that they create/enable cancer. Might the regulatory bodies come down more quickly now on pure pesticides in crop protection, because thay are seen as harmful to human life and if so, with Eden being one of only a few biopesticide companies in the world with proven products, commercially available and with regulatory approval, be seen as a leading light and the future?

I can't see how they cannot be. If viruses need vaccines to protect human life, crop protection needs biopesticides and more to protect human life.

In my opinion, Eden looks vastly undervalued and you can pick a number that you like, but 7p looks the steal of the century to me.

[devereaux] 23/3/2020 09:00

The 50,000 shown as a sale today is my buy.
Long live the Garden of Eden

[supersonico] 22/3/2020 19:21

Eugene and Mrs100K will be please as another road block looks to have been cleared. Just in time for the fund raise:)

PRESERVATIVES

Conclusion] The examiner's decision is revoked. The Invention of the present application shall be granted a patent.

[pugugly] 22/3/2020 17:44

ss_ Nothing specfic but a possible take from buying in to early in a faling market - but we all do this at times -

[supersonico] 22/3/2020 17:00

Not sure what your referring to PU regarding trials. Are you speculating? or do you have any supporting references for your comments?

[pugugly] 22/3/2020 14:48

Could also be an indication that they pump too much cash into failing trial and lack guts to pull the plug in time - bull all companies and investors make this mistake at some time - all that matters is that they come out on top - However as investors always looking for indicators - either way - and we have one above. Only time will tell.

[supersonico] 22/3/2020 13:38

That's always a possibility and so is the complete opposite of your assumption.

[pugugly] 22/3/2020 12:57

Just shows he has not got a clue ab out the stock market and the current and further potential impact of the virus - A negative in terms of management awareness - Could this also be a straw in the wind on management competence - Possilby always looking on the bright side - rather than facts as they are in reality?

[supersonico] 22/3/2020 08:10

In other news.

7 February 2020

The Executive VP & Chief Commercial Officer of Corteva, Inc. (NYSE:CTVA), Timothy Glenn, Just Bought 6.7% More Shares

[chrischas] 21/3/2020 17:52

All we need now is some sales

[pugugly] 21/3/2020 17:07

Corteva dropped from over $31 to $22.5 in last 6 weeks - OK know nyse is in meltdown but over the odds (imo)

[investingisatrickygame] 21/3/2020 10:14

Some in this financial downturn will go looking for stock market bargains, as well as stocks that are the future.

So again, Eden protects food supply
Has access to cheap and plentiful product supplies
Eden is and was pre-placing, debt free.
Eden is now cash rich
Eden is awaiting multiple regulatory approvals for Mevalone, including the USA
Eden is awaiting multiple regulatory approvals for Cedroz which has access to a global market value in Nematicides of $1.2 billion
Eden is knocking on the door with Corteva for a net €40 million annual revenues for their seed encapsulation and this is just in the EU
If Eden achieves the above as RNS'd in the Placing RNS, this will surely open up global market opportunities for the same and even greater net value to Eden
From the Placing RNS they are also to develop and commercialise the Company's first insecticide products

And then they have the flag waving credentials

Micro-plastic free formulation delivery via Sustaine
Controlled product release via Sustaine which can be adjusted for new markets
Organic status
Free from Maximum Residue Levels
Equivalent product performance without the pesticide label & associated footprint

And then we have the brags to aid the news stories

Eden is the only UK listed company focused on biopesticides for sustainable agriculture
Globally, Eden is one of a few biocontrol companies with proven products and regulatory authorisation
Eden has in its IP bank, 110 granted and pending patents

And then we have the opportunities

Pesticides coming off of regulatory approval
A biopesticide market set to reach $8.8 billion in two years time
Sustaine technology that can encapsulate a raft of crop protection products as well as blend formulations with Eden's natural solutions for future success
Possibilities to use Sustaine in Animal Health and Consumer products, in due course



If you were looking for a new investment opportunity as a private investor, those in charge of discretionary funds at Private Wealth management companies, a pension fund/institution or any other type of investor and you found Eden, a company that protects food supply, maintains or enhances crop yields in a sustainable and green way and has a plentiful supply of cheap product, you would surely see Eden as the future and you would surely see immense capital growth opportunities from 6p that you quite likely would not be seeing elsewhere in traditional products and sectors.

In my opinion, even in this decimated market, Eden now looks like the steal of the century.

The Corteva deal alone and just for the EU on a multiple of 10 with all the revenue going to the bottom line, by my maths, returns more than 10 times today's share price.

In my opinion, buyers should now be in the market and scrambling for stock.

Time will tell!

[supersonico] 20/3/2020 16:08

,Amati AIM VCT plc 4.45%



CANACCORD GENUITY GROUP INC

[supersonico] 20/3/2020 10:46

BGF 15.337%

[attyg] 19/3/2020 14:12

Money in the bank!

Good stuff.

[chrischas] 19/3/2020 13:35

AttyG: what revenues?

[attyg] 19/3/2020 08:31

Weak sterling - compared to US$ and € is good for us - our revenues are in FX.
Bizarre, but long may it continue!

[supersonico] 18/3/2020 13:56

Is it 2p already?

For someone who's seldom wrong I'm starting to see some issues in the simple task of reading the share price

Not a good start CredibleTrev.

Still you do make Mrs100K chuckle if that's any conciliation.